表紙
市場調查報告書
商品編碼
1066263

液體活檢美國市場:增長機會

United States Liquid Biopsy Growth Opportunities

出版日期: | 出版商: Frost & Sullivan | 英文 73 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

醫療保健正迅速以患者為中心,注重結果和價值觀。這使臨床診斷製造商有機會改進其設備、化驗和信息學能力,以滿足未滿足的臨床需求並擴大其精密診斷產品組合。

本報告探討美國液體活檢市場,提供有關市場動態、主要公司、投資和競爭環境、預測、治療(腫瘤學/非腫瘤學)和產品類型(試劑盒/試劑)的最新信息,我們提供設備分析/分析平台、檢驗/開發服務)、成長機會等。

目錄

戰略要求

  • 為什麼增長變得更加困難
  • 戰略要點 8 (TM)
  • 三大公司戰略要求對液體活檢市場的影響
  • 增長機會推動增長管道引擎 (TM)

生長機會分析-液體活檢

  • 分析範圍
  • 細分:按治療
  • 細分:按產品類型
  • 主要競爭對手:按產品類型/處理方法
  • 術語
  • 主要的基於 PCR 或 NGS 的 cfNA 分析方法
  • 液體活檢應用評論:癌症分析物
  • cfNA 在一系列癌症治療中的診斷應用
  • 主要增長指標
  • 生長促進劑
  • 生長抑製劑
  • 監管狀態
  • 預測的先決條件
  • 收入預測
  • 收入預測:按治療
  • 收入預測:按腫瘤產品/服務類型
  • 收入預測:按 NIPT 產品/服務類型
  • 收入預測:按其他產品/服務分類
  • 收入預測分析
  • 收入預測分析:按所選產品/服務
  • 收入預測分析:按治療
  • 競爭環境
  • 收入分成
  • 收益分享-腫瘤治療
  • 收入分成-NIPT 療法
  • 收入份額分析

成長機會分析-腫瘤學(治療段)

  • 主要增長指標
  • 收入預測-腫瘤治療
  • 利潤預測分析-腫瘤治療

增長機會分析-非腫瘤學(治療段)

  • 主要增長指標
  • 收入預測-非腫瘤治療
  • 預測分析-非腫瘤治療

競爭態勢分析

  • 競爭性生態系統
  • 競爭對手矩陣
  • 主要公司簡介
  • 各大公司產品矩陣
  • 融資趨勢
  • 合併/收購和合作

成長機會

  • 增長機會 1-將 AI-ML 用於液體活檢數據以識別新的生物標誌物
  • 增長機會 2-通過聯合開發夥伴關係將液體活檢 NGS 擴展為 CDx
  • 3-cfDNA 甲基化作為泛癌篩查生物標誌物的增長機會
  • Growth Opportunity 4-用於早期發現神經退行性疾□□病的液體活檢
  • 增長機會 5-全面的癌症分析,以改善醫院和實驗室的癌症管理

下一步

  • 下一步
  • 展品清單
  • 免責聲明
目錄
Product Code: K695-55

Non-invasive Liquid Biopsy Technology Shapes the Precision Diagnostics Landscape

Healthcare is rapidly becoming patient-centric, focusing on outcomes and value. This offers clinical diagnostics players opportunities to advance their instrument, assay, and informatics capabilities to address unmet clinical needs and increase the precision diagnostics portfolio.

Advances in next-generation sequencing-based companion diagnostics (CDx) and liquid biopsy (LBx) enable precision medicine approaches toward diseases such as cancer. Another aspect changing the diagnostics industry is linking automation to digital technologies to improve efficiency and productivity. This includes leveraging artificial intelligence to enhance workflow and accuracy.

Frost & Sullivan's analysis shows that the top 5 companies in the US liquid biopsy market-Exact Sciences, Guardant Health, Roche/Foundation Medicine, Natera, and LabCorp-account for 77.5% of its revenue in 2020. We expect the market to reach $7.02 billion by 2025 at a 14% CAGR.

The report provides updates on the competitive landscape by analyzing market dynamics, participants, and investments. It also offers stakeholders insights through forecasts, analysis by therapy (oncology and non-oncology) and product type (kits and reagents, instruments and analysis platforms, testing and development services), and growth opportunities.

Table of Contents

Strategic Imperatives

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top Three Strategic Imperatives on the Liquid Biopsy Market
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis-Liquid Biopsy

  • Scope of Analysis
  • Segmentation by Therapy
  • Segmentation by Product Type
  • Key Competitors by Product Type and Therapy
  • Terminologies
  • Major cfNA Analysis Methods are PCR- or NGS-based
  • Review of Liquid Biopsy Applications by Analytes in Cancer
  • cfNA Diagnostics Applications across the Cancer Care Continuum
  • Key Growth Metrics
  • Growth Drivers
  • Growth Restraints
  • Regulatory Landscape
  • Forecast Assumptions
  • Revenue Forecast
  • Revenue Forecast by Therapy
  • Revenue Forecast by Oncology Product/Service Type
  • Revenue Forecast by NIPT Product/Service Type
  • Revenue Forecast for Other Products/Services
  • Revenue Forecast Analysis
  • Revenue Forecast Analysis by Selected Products/Services
  • Revenue Forecast Analysis by Therapy
  • Competitive Environment
  • Revenue Share
  • Revenue Share-Oncology Therapy
  • Revenue Share-NIPT Therapy
  • Revenue Share Analysis

Growth Opportunity Analysis-Oncology (Therapy Segment)

  • Key Growth Metrics
  • Revenue Forecast-Oncology Therapy
  • Revenue Forecast Analysis-Oncology Therapy

Growth Opportunity Analysis-Non-oncology (Therapy Segment)

  • Key Growth Metrics
  • Revenue Forecast-Non-oncology Therapy
  • Revenue Forecast Analysis-Non-oncology Therapy

Competitive Landscape Analysis

  • Competitive Ecosystem
  • Competitor Matrix
  • Competitor Matrix (continued)
  • Key Company Profiles
  • Key Company Profiles (continued)
  • Key Company Profiles (continued)
  • Key Company Product Matrix
  • Funding Trends
  • Mergers & Acquisitions and Partnerships
  • Mergers & Acquisitions and Partnerships (continued)

Growth Opportunity Universe

  • Growth Opportunity 1-Use AI-ML on Liquid Biopsy Data to Identify Novel Biomarkers
  • Growth Opportunity 1-Use AI-ML on Liquid Biopsy Data to Identify Novel Biomarkers (continued)
  • Growth Opportunity 2-Expand Liquid Biopsy NGS as CDx through Co-development Partnerships
  • Growth Opportunity 2-Expand Liquid Biopsy NGS as CDx through Co-development Partnerships (continued)
  • Growth Opportunity 3-cfDNA Methylation as a Pan-cancer Screening Biomarker
  • Growth Opportunity 3-cfDNA Methylation as a Pan-cancer Screening Biomarker (continued)
  • Growth Opportunity 4-Liquid Biopsy for Early Neurodegenerative Disease Detection
  • Growth Opportunity 4-Liquid Biopsy for Early Neurodegenerative Disease Detection (continued)
  • Growth Opportunity 5-Comprehensive Cancer Profiling to Improve Cancer Management for Hospitals and Laboratories
  • Growth Opportunity 5-Comprehensive Cancer Profiling to Improve Cancer Management for Hospitals and Laboratories (continued)

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • List of Exhibits
  • List of Exhibits (continued)
  • Legal Disclaimer